No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
90 |
4. Check minimum number of eventsNone |
90 |
5. Include endpointsNone |
90 |
6. Filter based on genotype QC (FinnGen only) |
84 |
Control definitions (FinnGen only)
- Control exclude
- D3_HAEMOLYTICANAEMIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D59
- Name in latin
- Syndroma haemolytico-uraemicum
Similar endpoints
↥List of similar endpoints to
Haemolytic-uraemic syndrome
based on the number of shared cases.
Similar with more cases:
- Acquired haemolytic anaemia
- Haemolytic anaemias
- Anaemias
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 569 | 325 | 242 |
| Only index persons | 445 | 258 | 187 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 25.46 | 26.20 | 24.21 |
| Only index persons | 25.69 | 26.59 | 24.44 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 84 | 47 | 37 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 37.91 | 31.58 | 45.96 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 90
- Matched controls
- 900
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D59.3
ICD-10 Finland
Haemolytic-uraemic syndrome
+∞
73.2
60
*
N08.2*D59.3
ICD-10 Finland
Glomerular disorders in haemolytic-uraemic syndrome
+∞
59.0
50
*
TK800
NOMESCO Finland
Hemodialysis
100.8
38.2
40
7
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
21.1
37.7
33
24
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
84.0
36.2
39
8
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
84.0
36.2
39
8
A11CC03
ATC
alfacalcidol; systemic
72.8
30.0
33
7
Z94.0
ICD-10 Finland
Kidney transplant status
147.4
29.8
30
*
H02AB04
ATC
methylprednisolone; systemic
12.7
28.6
35
43
A12AA04
ATC
calcium carbonate; oral
133.2
27.5
28
*
127
Kela drug reimbursment
Transplant complication
57.9
27.1
31
8
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
126.4
26.3
27
*
L04AA06
ATC
mycophenolic acid; systemic
55.1
26.0
30
8
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
36.3
25.9
33
14
N08.2*D89.80
ICD-10 Finland
Immunoglobulin A (IgA) nephropathy
+∞
25.2
23
*
Z49.1
ICD-10 Finland
Extracorporeal dialysis
75.9
24.7
27
5
N18.0
ICD-10 Finland
End-stage renal disease
161.2
23.9
24
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
8.8
23.6
43
85
B03XA02
ATC
darbepoetin alfa; parenteral
54.0
23.3
27
7
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
286.9
22.7
22
*
C09AA02
ATC
enalapril; systemic
8.9
21.8
36
63
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
270.0
21.6
21
*
C03CA01
ATC
furosemide; systemic
7.4
20.3
45
107
L04AD02
ATC
tacrolimus; systemic
40.1
19.6
24
8
WW400
NOMESCO Finland
Plasmaferesis
+∞
19.5
18
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
7.8
19.1
35
68
V03AE01
ATC
polystyrene sulfonate; oral
67.5
18.9
21
*
N08.2
ICD-10 Finland
Glomerular disorders in blood diseases and disorders involving the immune mechanism
+∞
18.3
17
*
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
118.9
18.3
19
*
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
53.8
18.2
21
5
205
Kela drug reimbursment
Chronic hypertension
6.6
17.3
40
97
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
59.4
16.8
19
*
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
68.9
15.4
17
*
137
Kela drug reimbursment
Uraemia requiring dialysis
95.7
15.1
16
*
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
18.8
15.1
23
16
C02AC05
ATC
moxonidine; oral
28.0
15.0
20
9
D89.80
ICD-10 Finland
Immunoglobulin A (IgA) deposits in organisms
+∞
15.0
14
*
KA1AE
NOMESCO Finland
Kidney ultrasound examination
33.8
15.0
19
7
Z49.0
ICD-10 Finland
Preparatory care for dialysis
177.7
14.9
15
*
C08CA01
ATC
amlodipine; oral
5.6
14.9
52
178
WX408
NOMESCO Finland
General anesthesy, balanced
5.4
14.2
45
141
Z2446
NOMESCO Finland
Social worker
7.1
14.2
26
49
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
88.6
14.0
15
*
Z3231
NOMESCO Finland
Registered nurse
5.2
13.7
48
163
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
59.2
13.3
15
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
21.5
13.2
19
11
L04AA01
ATC
[U] ciclosporin
81.8
13.0
14
*
V03AE02
ATC
sevelamer; oral
81.8
13.0
14
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.1
12.9
60
252
N18.8
ICD-10 Finland
Other chronic renal failure
25.7
12.6
17
8
N17.9
ICD-10 Finland
Acute renal failure, unspecified
18.1
12.5
19
13
B03XA01
ATC
erythropoietin; parenteral
54.6
12.3
14
*
M31.1
ICD-10 Finland
Thrombotic microangiopathy
+∞
11.7
11
*
KA9AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
11.7
11
*
N25.8
ICD-10 Finland
Other disorders resulting from impaired renal tubular function
+∞
11.7
11
*
L04AD01
ATC
ciclosporin; systemic
29.6
11.6
15
6
R4110
NOMESCO Finland
Physiotherapy
4.5
11.4
43
151
B05DB
ATC
Hypertonic solutions
123.8
10.7
11
*
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
123.8
10.7
11
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
5.1
10.7
28
73
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
12.9
10.4
18
17
ZX120
NOMESCO Finland
Intravenous
6.0
9.9
20
41
196
Kela drug reimbursment
Paricalcitol and cinacalcet
111.2
9.6
10
*
B05DA
ATC
Isotonic solutions
111.2
9.6
10
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
6.1
9.6
19
38
ZXA00
NOMESCO Finland
Right side
4.5
9.6
31
95
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.0
9.3
41
157
Z2221
NOMESCO Finland
Medical doctor
3.9
9.3
42
164
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
41.2
9.2
11
*
ZXE00
NOMESCO Finland
One hour or less
3.9
9.1
54
252
ZXE10
NOMESCO Finland
More than one and less than three hours
3.8
9.0
46
194
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
8.6
8.8
19
27
XF655
NOMESCO Finland
Measurement of heart muscle perfusion with exercise
30.9
8.7
11
*
ZXD05
NOMESCO Finland
Urgent procedure
3.7
8.7
44
184
Z3226
NOMESCO Finland
Physiotherapist
4.0
8.6
32
108
ZXE20
NOMESCO Finland
More than three and less than five hours
4.7
8.6
24
65
Z49.2
ICD-10 Finland
Other dialysis
98.9
8.6
9
*
N08.5*M31.1
ICD-10 Finland
Glomerular disorders in thrombotic thrombocytopenic purpura
+∞
8.5
8
*
N03.9
ICD-10 Finland
Chronic nephritic syndrome, unspecified
+∞
8.5
8
*
C07AG02
ATC
carvedilol; oral
11.7
8.4
15
15
H05BX01
ATC
cinacalcet; oral
49.4
7.9
9
*
M04AA01
ATC
allopurinol; systemic
5.2
7.8
18
41
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
9.2
7.5
15
19
RD210, ,
NOMESCO Finland
17.6
7.4
11
7
PBU84
NOMESCO Finland
Plastic repair of arteriovenous fistula from artery of upper extremity
+∞
7.4
7
*
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
32.9
7.3
9
*
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
32.9
7.3
9
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
7.1
29
103
JAK10
NOMESCO Finland
Laparotomy and insertion of peritoneal dialysis catheter
43.5
6.9
8
*
TK810
NOMESCO Finland
Hemofiltration
43.5
6.9
8
*
C02CA01
ATC
prazosin; oral
43.5
6.9
8
*
C07AB02
ATC
metoprolol; systemic
3.8
6.6
24
78
TJA35
NOMESCO Finland
Removal of peritoneal dialysis catheter
74.9
6.5
7
*
C08CA02
ATC
felodipine; oral
7.3
6.5
15
24
3025
Kela drug reimbursment
Calcium carbonate
28.9
6.3
8
*
L04AA05
ATC
[U] tacrolimus
28.9
6.3
8
*
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
7.7
6.3
14
21
A12AA12
ATC
[U] calcium acetate
+∞
6.3
6
*
V03AE03
ATC
lanthanum carbonate; oral
+∞
6.3
6
*
ZST00
NOMESCO Finland
Procedure related to previous procedure classified in chapter T
+∞
6.3
6
*
WX002
NOMESCO Finland
Sedation and analgesia
3.7
6.2
23
76
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
8.3e-01
2.0e+00
2.6e+00
—
3.8e+00
2.7e+00
1.9e+00
cases:10.26%
controls:4.75%
cases:18.52%
controls:2.97%
cases:14.81%
controls:1.24%
—
—
cases:24.68%
controls:0.74%
cases:28.77%
controls:2.74%
cases:36.23%
controls:7.50%
8
37
70
742
15
24
66
783
12
10
69
797
—
19
6
58
801
21
22
52
780
25
56
44
691
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
4.5e-01
1.3e+00
2.6e+00
—
3.7e+00
2.7e+00
1.9e+00
cases:8.97%
controls:5.91%
cases:13.58%
controls:3.97%
cases:13.58%
controls:1.12%
—
—
cases:28.57%
controls:0.99%
cases:28.77%
controls:2.74%
cases:37.68%
controls:8.57%
7
46
71
733
11
32
70
775
11
9
70
798
—
22
8
55
799
21
22
52
780
26
64
43
683
Internal Medicine
11 [38004456]
11 [38004456]
1.1e+00
1.9e+00
2.5e+00
1.0e+50
3.2e+00
1.6e+00
1.2e+00
cases:38.46%
controls:17.20%
cases:25.93%
controls:5.08%
cases:12.35%
controls:1.12%
cases:27.16%
controls:0.00%
cases:18.18%
controls:0.87%
cases:28.77%
controls:7.48%
cases:44.93%
controls:19.54%
30
134
48
645
21
41
60
766
10
9
71
798
22
0
59
807
14
7
63
800
21
60
52
742
31
146
38
601
Outpatient Visit
OP [9202]
OP [9202]
8.6e-01
1.5e+00
1.4e+00
4.3e+00
2.0e+00
2.2e+00
1.2e+00
cases:79.49%
controls:62.00%
cases:80.25%
controls:46.72%
cases:38.27%
controls:12.89%
cases:40.74%
controls:0.87%
cases:50.65%
controls:12.64%
cases:89.04%
controls:47.13%
cases:89.86%
controls:72.82%
62
483
16
296
65
377
16
430
31
104
50
703
33
7
48
800
39
102
38
705
65
378
8
424
62
544
7
203
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
1.8e-01
1.8e+00
2.8e+00
1.0e+50
2.9e+00
1.7e+00
1.3e+00
cases:6.41%
controls:5.39%
cases:17.28%
controls:3.47%
cases:14.81%
controls:0.99%
cases:8.64%
controls:0.00%
cases:18.18%
controls:1.24%
cases:17.81%
controls:3.62%
cases:27.54%
controls:8.97%
5
42
73
737
14
28
67
779
12
8
69
799
7
0
74
807
14
10
63
797
13
29
60
773
19
67
50
680
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
1.3e+00
1.4e+00
2.8e+00
—
2.4e+00
2.4e+00
1.4e+00
cases:8.97%
controls:2.57%
cases:13.58%
controls:3.59%
cases:11.11%
controls:0.74%
—
—
cases:10.39%
controls:0.99%
cases:26.03%
controls:2.99%
cases:31.88%
controls:10.31%
7
20
71
759
11
29
70
778
9
6
72
801
—
8
8
69
799
19
24
54
778
22
77
47
670
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
3.4e-01
1.2e+00
2.4e+00
—
3.6e+00
2.5e+00
1.7e+00
cases:8.97%
controls:6.55%
cases:14.81%
controls:4.96%
cases:14.81%
controls:1.49%
—
—
cases:28.57%
controls:1.12%
cases:30.14%
controls:3.24%
cases:37.68%
controls:10.04%
7
51
71
728
12
40
69
767
12
12
69
795
—
22
9
55
798
22
26
51
776
26
75
43
672
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
1.5e+00
1.7e+00
3.0e+00
1.0e+50
—
2.9e+00
2.5e+00
cases:6.41%
controls:1.54%
cases:11.11%
controls:2.23%
cases:11.11%
controls:0.62%
cases:8.64%
controls:0.00%
—
—
cases:28.77%
controls:2.12%
cases:28.99%
controls:3.21%
5
12
73
767
9
18
72
789
9
5
72
802
7
0
74
807
—
21
17
52
785
20
24
49
723
furosemide; oral, parenteral
C03CA01 [21601518]
C03CA01 [21601518]
2.4e+00
2.7e+00
—
—
—
2.6e+00
2.2e+00
cases:25.64%
controls:3.08%
cases:24.69%
controls:2.11%
—
—
—
—
—
—
cases:28.77%
controls:2.87%
cases:30.43%
controls:4.69%
20
24
58
755
20
17
61
790
—
—
—
21
23
52
779
21
35
48
712
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
—
1.6e+00
—
—
3.6e+00
3.0e+00
2.6e+00
—
—
cases:9.88%
controls:2.11%
—
—
—
—
cases:22.08%
controls:0.74%
cases:23.29%
controls:1.50%
cases:23.19%
controls:2.14%
—
8
17
73
790
—
—
17
6
60
801
17
12
56
790
16
16
53
731
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
8.3e-01
2.0e+00
2.5e+00
—
—
2.3e+00
1.9e+00
cases:8.97%
controls:4.11%
cases:13.58%
controls:1.98%
cases:7.41%
controls:0.62%
—
—
—
—
cases:21.92%
controls:2.62%
cases:30.43%
controls:6.29%
7
32
71
747
11
16
70
791
6
5
75
802
—
—
16
21
57
781
21
47
48
700
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
7.7e-01
2.0e+00
2.5e+00
—
—
2.3e+00
1.9e+00
cases:7.69%
controls:3.72%
cases:13.58%
controls:1.98%
cases:7.41%
controls:0.62%
—
—
—
—
cases:20.55%
controls:2.49%
cases:27.54%
controls:5.49%
6
29
72
750
11
16
70
791
6
5
75
802
—
—
15
20
58
782
19
41
50
706
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
-4.8e-02
1.1e+00
2.4e+00
—
2.5e+00
1.4e+00
1.2e+00
cases:8.97%
controls:9.37%
cases:18.52%
controls:6.94%
cases:14.81%
controls:1.49%
—
—
cases:18.18%
controls:1.73%
cases:26.03%
controls:7.73%
cases:37.68%
controls:15.66%
7
73
71
706
15
56
66
751
12
12
69
795
—
14
14
63
793
19
62
54
740
26
117
43
630
calcium (different salts in combination); oral
A12AA20 [21600872]
A12AA20 [21600872]
6.5e-01
1.3e+00
—
—
2.7e+00
2.4e+00
2.0e+00
cases:8.97%
controls:4.88%
cases:13.58%
controls:3.97%
—
—
—
—
cases:10.39%
controls:0.74%
cases:27.40%
controls:3.24%
cases:27.54%
controls:5.09%
7
38
71
741
11
32
70
775
—
—
8
6
69
801
20
26
53
776
19
38
50
709
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
6.5e-01
1.9e+00
2.4e+00
—
—
2.2e+00
1.7e+00
cases:8.97%
controls:4.88%
cases:13.58%
controls:2.23%
cases:7.41%
controls:0.74%
—
—
—
—
cases:21.92%
controls:2.87%
cases:30.43%
controls:7.10%
7
38
71
741
11
18
70
789
6
6
75
801
—
—
16
23
57
779
21
53
48
694
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
1.2e+00
2.2e+00
—
1.0e+50
—
2.6e+00
2.2e+00
cases:16.67%
controls:5.65%
cases:17.28%
controls:2.23%
—
—
cases:11.11%
controls:0.00%
—
—
cases:16.44%
controls:1.37%
cases:39.13%
controls:6.69%
13
44
65
735
14
18
67
789
—
9
0
72
807
—
12
11
61
791
27
50
42
697
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
6.3e-01
1.9e+00
2.2e+00
—
—
2.1e+00
1.8e+00
cases:7.69%
controls:4.24%
cases:13.58%
controls:2.35%
cases:7.41%
controls:0.87%
—
—
—
—
cases:20.55%
controls:3.12%
cases:31.88%
controls:7.36%
6
33
72
746
11
19
70
788
6
7
75
800
—
—
15
25
58
777
22
55
47
692
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
2731-8 [3000067]
—
2.1e+00
—
—
—
2.7e+00
3.0e+00
—
—
cases:8.64%
controls:1.12%
—
—
—
—
—
—
cases:19.18%
controls:1.50%
cases:24.64%
controls:1.61%
—
7
9
74
798
—
—
—
14
12
59
790
17
12
52
735
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
5.5e-01
2.0e+00
2.2e+00
—
—
2.1e+00
1.5e+00
cases:8.97%
controls:5.39%
cases:14.81%
controls:2.35%
cases:7.41%
controls:0.87%
—
—
—
—
cases:21.92%
controls:3.37%
cases:31.88%
controls:9.10%
7
42
71
737
12
19
69
788
6
7
75
800
—
—
16
27
57
775
22
68
47
679
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
2.0e+00
2.2e+00
—
—
—
3.1e+00
2.4e+00
cases:6.41%
controls:0.90%
cases:12.35%
controls:1.49%
—
—
—
—
—
—
cases:26.03%
controls:1.50%
cases:26.09%
controls:3.21%
5
7
73
772
10
12
71
795
—
—
—
19
12
54
790
18
24
51
723
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
4.7e-02
1.2e+00
1.8e+00
—
2.3e+00
1.2e+00
1.3e+00
cases:8.97%
controls:8.60%
cases:18.52%
controls:6.69%
cases:12.35%
controls:2.23%
—
—
cases:18.18%
controls:2.23%
cases:19.18%
controls:6.73%
cases:37.68%
controls:14.46%
7
67
71
712
15
54
66
753
10
18
71
789
—
14
18
63
789
14
54
59
748
26
108
43
639
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
33863-2 [3030366]
—
—
—
—
2.7e+00
2.4e+00
2.5e+00
—
—
—
—
—
—
—
—
cases:11.69%
controls:0.87%
cases:15.07%
controls:1.62%
cases:17.39%
controls:1.74%
—
—
—
—
9
7
68
800
11
13
62
789
12
13
57
734
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
1.9e+00
—
—
—
—
2.5e+00
3.0e+00
cases:10.26%
controls:1.67%
—
—
—
—
—
—
—
—
cases:12.33%
controls:1.12%
cases:21.74%
controls:1.34%
8
13
70
766
—
—
—
—
9
9
64
793
15
10
54
737
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
2.0e+00
2.1e+00
—
—
—
3.1e+00
2.2e+00
cases:6.41%
controls:0.90%
cases:12.35%
controls:1.61%
—
—
—
—
—
—
cases:24.66%
controls:1.50%
cases:24.64%
controls:3.48%
5
7
73
772
10
13
71
794
—
—
—
18
12
55
790
17
26
52
721
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
1.1e+00
2.0e+00
—
—
—
3.4e+00
2.0e+00
cases:7.69%
controls:2.57%
cases:11.11%
controls:1.73%
—
—
—
—
—
—
cases:23.29%
controls:1.00%
cases:28.99%
controls:5.09%
6
20
72
759
9
14
72
793
—
—
—
17
8
56
794
20
38
49
709
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
2.0e+00
2.0e+00
—
—
—
3.0e+00
2.3e+00
cases:6.41%
controls:0.90%
cases:12.35%
controls:1.86%
—
—
—
—
—
—
cases:24.66%
controls:1.62%
cases:26.09%
controls:3.35%
5
7
73
772
10
15
71
792
—
—
—
18
13
55
789
18
25
51
722
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
8.8e-01
1.2e+00
1.8e+00
—
2.6e+00
1.6e+00
8.1e-01
cases:24.36%
controls:11.81%
cases:16.05%
controls:5.45%
cases:8.64%
controls:1.49%
—
—
cases:12.99%
controls:1.12%
cases:24.66%
controls:5.99%
cases:26.09%
controls:13.52%
19
92
59
687
13
44
68
763
7
12
74
795
—
10
9
67
798
18
48
55
754
18
101
51
646
amlodipine; oral
C08CA01 [21601747]
C08CA01 [21601747]
1.3e+00
1.4e+00
—
—
2.4e+00
2.0e+00
1.0e+00
cases:19.23%
controls:5.91%
cases:16.05%
controls:4.71%
—
—
—
—
cases:16.88%
controls:1.86%
cases:28.77%
controls:5.36%
cases:21.74%
controls:8.97%
15
46
63
733
13
38
68
769
—
—
13
15
64
792
21
43
52
759
15
67
54
680
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
2.4e-01
9.9e-01
1.8e+00
—
2.2e+00
1.3e+00
1.4e+00
cases:8.97%
controls:7.19%
cases:14.81%
controls:6.07%
cases:9.88%
controls:1.86%
—
—
cases:14.29%
controls:1.73%
cases:17.81%
controls:5.74%
cases:33.33%
controls:11.11%
7
56
71
723
12
49
69
758
8
15
73
792
—
11
14
66
793
13
46
60
756
23
83
46
664
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
2.2e-01
1.0e+00
1.8e+00
1.0e+50
2.5e+00
1.2e+00
1.2e+00
cases:8.97%
controls:7.32%
cases:14.81%
controls:5.82%
cases:9.88%
controls:1.86%
cases:6.17%
controls:0.00%
cases:16.88%
controls:1.61%
cases:17.81%
controls:6.11%
cases:33.33%
controls:13.39%
7
57
71
722
12
47
69
760
8
15
73
792
5
0
76
807
13
13
64
794
13
49
60
753
23
100
46
647
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
2.4e-01
9.9e-01
1.8e+00
—
2.2e+00
1.3e+00
1.4e+00
cases:8.97%
controls:7.19%
cases:14.81%
controls:6.07%
cases:9.88%
controls:1.86%
—
—
cases:14.29%
controls:1.73%
cases:17.81%
controls:5.74%
cases:33.33%
controls:11.24%
7
56
71
723
12
49
69
758
8
15
73
792
—
11
14
66
793
13
46
60
756
23
84
46
663
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
2.4e-01
9.9e-01
1.8e+00
—
2.2e+00
1.3e+00
1.4e+00
cases:8.97%
controls:7.19%
cases:14.81%
controls:6.07%
cases:9.88%
controls:1.86%
—
—
cases:14.29%
controls:1.73%
cases:17.81%
controls:5.74%
cases:33.33%
controls:11.24%
7
56
71
723
12
49
69
758
8
15
73
792
—
11
14
66
793
13
46
60
756
23
84
46
663
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
2.0e-01
1.1e+00
1.8e+00
1.0e+50
2.2e+00
1.2e+00
1.3e+00
cases:8.97%
controls:7.45%
cases:16.05%
controls:6.07%
cases:9.88%
controls:1.86%
cases:6.17%
controls:0.00%
cases:14.29%
controls:1.86%
cases:17.81%
controls:5.99%
cases:33.33%
controls:11.78%
7
58
71
721
13
49
68
758
8
15
73
792
5
0
76
807
11
15
66
792
13
48
60
754
23
88
46
659
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
3.0e-01
1.1e+00
1.8e+00
—
2.2e+00
1.2e+00
1.2e+00
cases:8.97%
controls:6.80%
cases:14.81%
controls:5.70%
cases:9.88%
controls:1.73%
—
—
cases:12.99%
controls:1.61%
cases:17.81%
controls:6.11%
cases:33.33%
controls:12.85%
7
53
71
726
12
46
69
761
8
14
73
793
—
10
13
67
794
13
49
60
753
23
96
46
651
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
3.0e-01
1.1e+00
1.8e+00
—
2.2e+00
1.2e+00
1.2e+00
cases:8.97%
controls:6.80%
cases:14.81%
controls:5.70%
cases:9.88%
controls:1.73%
—
—
cases:12.99%
controls:1.61%
cases:17.81%
controls:6.11%
cases:33.33%
controls:12.85%
7
53
71
726
12
46
69
761
8
14
73
793
—
10
13
67
794
13
49
60
753
23
96
46
651
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
1.3e+00
1.7e+00
—
1.0e+50
—
2.7e+00
2.3e+00
cases:15.38%
controls:4.62%
cases:8.64%
controls:1.73%
—
—
cases:7.41%
controls:0.00%
—
—
cases:17.81%
controls:1.37%
cases:20.29%
controls:2.41%
12
36
66
743
7
14
74
793
—
6
0
75
807
—
13
11
60
791
14
18
55
729
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
1.8e+00
2.4e+00
—
—
—
—
2.2e+00
cases:10.26%
controls:1.93%
cases:7.41%
controls:0.74%
—
—
—
—
—
—
—
—
cases:15.94%
controls:2.01%
8
15
70
764
6
6
75
801
—
—
—
—
11
15
58
732
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
2.2e-01
1.0e+00
1.8e+00
—
2.1e+00
1.2e+00
1.2e+00
cases:8.97%
controls:7.32%
cases:14.81%
controls:5.82%
cases:9.88%
controls:1.73%
—
—
cases:12.99%
controls:1.73%
cases:17.81%
controls:6.36%
cases:33.33%
controls:12.85%
7
57
71
722
12
47
69
760
8
14
73
793
—
10
14
67
793
13
51
60
751
23
96
46
651
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
1.3e+00
—
—
—
—
2.2e+00
2.3e+00
cases:19.23%
controls:5.91%
—
—
—
—
—
—
—
—
cases:13.70%
controls:1.75%
cases:23.19%
controls:2.95%
15
46
63
733
—
—
—
—
10
14
63
788
16
22
53
725
enalapril; oral, parenteral
C09AA02 [21601786]
C09AA02 [21601786]
1.9e+00
1.4e+00
—
—
2.1e+00
1.2e+00
1.7e+00
cases:19.23%
controls:3.34%
cases:9.88%
controls:2.60%
—
—
—
—
cases:7.79%
controls:0.99%
cases:9.59%
controls:3.12%
cases:18.84%
controls:4.15%
15
26
63
753
8
21
73
786
—
—
6
8
71
799
7
25
66
777
13
31
56
716
Emergency Room Visit
ER [9203]
ER [9203]
4.6e-01
9.2e-01
2.4e+00
—
2.4e+00
6.9e-01
8.8e-01
cases:44.87%
controls:33.89%
cases:25.93%
controls:12.27%
cases:20.99%
controls:2.23%
—
—
cases:18.18%
controls:1.98%
cases:20.55%
controls:11.47%
cases:55.07%
controls:33.73%
35
264
43
515
21
99
60
708
17
18
64
789
—
14
16
63
791
15
92
58
710
38
252
31
495
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
1.4e+00
1.2e+00
—
—
—
2.1e+00
2.2e+00
cases:19.23%
controls:5.39%
cases:6.17%
controls:1.86%
—
—
—
—
—
—
cases:13.70%
controls:1.87%
cases:15.94%
controls:2.14%
15
42
63
737
5
15
76
792
—
—
—
10
15
63
787
11
16
58
731
moxonidine; oral
C02AC05 [21600401]
C02AC05 [21600401]
2.9e+00
—
—
—
—
—
2.8e+00
cases:10.26%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:10.14%
controls:0.67%
8
5
70
774
—
—
—
—
—
7
5
62
742
Gas panel - Venous blood
24339-4 [3000991]
24339-4 [3000991]
—
1.7e+00
—
—
—
3.0e+00
2.6e+00
—
—
cases:7.41%
controls:1.49%
—
—
—
—
—
—
cases:15.07%
controls:0.87%
cases:23.19%
controls:2.28%
—
6
12
75
795
—
—
—
11
7
62
795
16
17
53
730
Inpatient Hospital
21 [8717]
21 [8717]
3.3e-01
9.6e-01
1.8e+00
—
2.7e+00
9.4e-01
4.0e-01
cases:44.87%
controls:36.84%
cases:27.16%
controls:12.52%
cases:13.58%
controls:2.48%
—
—
cases:25.97%
controls:2.23%
cases:26.03%
controls:12.09%
cases:37.68%
controls:28.92%
35
287
43
492
22
101
59
706
11
20
70
787
—
20
18
57
789
19
97
54
705
26
216
43
531
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-1.0e+00
—
—
—
—
2.7e+00
2.8e+00
cases:11.54%
controls:26.96%
—
—
—
—
—
—
—
—
cases:8.22%
controls:0.62%
cases:17.39%
controls:1.20%
9
210
69
569
—
—
—
—
6
5
67
797
12
9
57
738
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
-3.1e-01
4.8e-01
1.6e+00
—
2.8e+00
1.1e+00
6.5e-01
cases:12.82%
controls:16.69%
cases:20.99%
controls:14.13%
cases:18.52%
controls:4.34%
—
—
cases:29.87%
controls:2.60%
cases:32.88%
controls:14.34%
cases:44.93%
controls:29.85%
10
130
68
649
17
114
64
693
15
35
66
772
—
23
21
54
786
24
115
49
687
31
223
38
524
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
-3.2e-01
4.6e-01
1.6e+00
—
2.8e+00
1.1e+00
6.9e-01
cases:12.82%
controls:16.82%
cases:20.99%
controls:14.37%
cases:18.52%
controls:4.34%
—
—
cases:29.87%
controls:2.60%
cases:32.88%
controls:14.59%
cases:46.38%
controls:30.25%
10
131
68
648
17
116
64
691
15
35
66
772
—
23
21
54
786
24
117
49
685
32
226
37
521
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
3.1e-01
9.9e-01
1.9e+00
1.0e+50
2.3e+00
1.1e+00
1.3e+00
cases:7.69%
controls:5.78%
cases:14.81%
controls:6.07%
cases:11.11%
controls:1.86%
cases:7.41%
controls:0.00%
cases:15.58%
controls:1.86%
cases:16.44%
controls:5.99%
cases:30.43%
controls:11.11%
6
45
72
734
12
49
69
758
9
15
72
792
6
0
75
807
12
15
65
792
12
48
61
754
21
83
48
664
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
4679-7 [3027945]
1.7e+00
—
—
—
—
3.0e+00
2.4e+00
cases:6.41%
controls:1.28%
—
—
—
—
—
—
—
—
cases:16.44%
controls:1.00%
cases:18.84%
controls:2.01%
5
10
73
769
—
—
—
—
12
8
61
794
13
15
56
732
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
5.4e-02
8.9e-01
1.8e+00
—
2.2e+00
1.1e+00
1.4e+00
cases:7.69%
controls:7.32%
cases:13.58%
controls:6.07%
cases:9.88%
controls:1.86%
—
—
cases:14.29%
controls:1.86%
cases:16.44%
controls:6.11%
cases:33.33%
controls:11.38%
6
57
72
722
11
49
70
758
8
15
73
792
—
11
15
66
792
12
49
61
753
23
85
46
662
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
-2.6e-01
7.0e-01
1.5e+00
1.0e+50
2.6e+00
1.2e+00
6.2e-01
cases:14.10%
controls:17.59%
cases:22.22%
controls:12.39%
cases:17.28%
controls:4.58%
cases:17.28%
controls:0.00%
cases:28.57%
controls:2.85%
cases:32.88%
controls:12.97%
cases:43.48%
controls:29.18%
11
137
67
642
18
100
63
707
14
37
67
770
14
0
67
807
22
23
55
784
24
104
49
698
30
218
39
529
allopurinol; oral, parenteral
M04AA01 [21604131]
M04AA01 [21604131]
2.7e+00
2.5e+00
—
—
—
—
1.5e+00
cases:10.26%
controls:0.77%
cases:9.88%
controls:0.87%
—
—
—
—
—
—
—
—
cases:8.70%
controls:2.01%
8
6
70
773
8
7
73
800
—
—
—
—
6
15
63
732
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
19232-8 [3007628]
—
1.8e+00
—
1.0e+50
—
2.8e+00
2.4e+00
—
—
cases:7.41%
controls:1.36%
—
—
cases:6.17%
controls:0.00%
—
—
cases:12.33%
controls:0.87%
cases:21.74%
controls:2.41%
—
6
11
75
796
—
5
0
76
807
—
9
7
64
795
15
18
54
729
carvedilol; oral
C07AG02 [21601700]
C07AG02 [21601700]
2.2e+00
2.4e+00
—
—
—
2.8e+00
2.1e+00
cases:6.41%
controls:0.77%
cases:6.17%
controls:0.62%
—
—
—
—
—
—
cases:9.59%
controls:0.62%
cases:7.25%
controls:0.94%
5
6
73
773
5
5
76
802
—
—
—
7
5
66
797
5
7
64
740
candesartan; oral
C09CA06 [21601829]
C09CA06 [21601829]
1.8e+00
1.8e+00
—
—
—
1.6e+00
1.6e+00
cases:12.82%
controls:2.31%
cases:9.88%
controls:1.86%
—
—
—
—
—
—
cases:9.59%
controls:2.12%
cases:17.39%
controls:4.15%
10
18
68
761
8
15
73
792
—
—
—
7
17
66
785
12
31
57
716
Nephrology
39 [38004479]
39 [38004479]
—
—
—
1.0e+50
—
—
5.1e+00
—
—
—
—
—
—
cases:27.16%
controls:0.00%
—
—
—
—
cases:53.62%
controls:0.67%
—
—
—
22
0
59
807
—
—
37
5
32
742
Base excess in Venous blood by calculation
1927-3 [3002032]
1927-3 [3002032]
—
1.5e+00
—
—
—
2.9e+00
2.2e+00
—
—
cases:7.41%
controls:1.73%
—
—
—
—
—
—
cases:15.07%
controls:1.00%
cases:21.74%
controls:3.08%
—
6
14
75
793
—
—
—
11
8
62
794
15
23
54
724
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
2021-4 [3021447]
—
1.5e+00
—
—
—
2.9e+00
2.1e+00
—
—
cases:7.41%
controls:1.73%
—
—
—
—
—
—
cases:15.07%
controls:1.00%
cases:21.74%
controls:3.21%
—
6
14
75
793
—
—
—
11
8
62
794
15
24
54
723
pH of Venous blood
2746-6 [3012544]
2746-6 [3012544]
—
1.5e+00
—
—
—
2.7e+00
2.2e+00
—
—
cases:7.41%
controls:1.73%
—
—
—
—
—
—
cases:15.07%
controls:1.12%
cases:21.74%
controls:3.08%
—
6
14
75
793
—
—
—
11
9
62
793
15
23
54
724
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
1.0e-01
3.1e-01
1.4e+00
—
2.4e+00
1.1e+00
7.4e-01
cases:16.67%
controls:15.28%
cases:18.52%
controls:14.25%
cases:19.75%
controls:5.58%
—
—
cases:29.87%
controls:3.84%
cases:31.51%
controls:13.34%
cases:42.03%
controls:25.70%
13
119
65
660
15
115
66
692
16
45
65
762
—
23
31
54
776
23
107
50
695
29
192
40
555
Vascular Surgery
77 [38004496]
77 [38004496]
2.8e+00
—
—
—
—
—
2.0e+00
cases:12.82%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
cases:11.59%
controls:1.74%
10
7
68
772
—
—
—
—
—
8
13
61
734
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
16933-4 [3021879]
—
—
—
—
—
2.7e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:8.22%
controls:0.62%
cases:10.14%
controls:1.47%
—
—
—
—
—
6
5
67
797
7
11
62
736
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
75622-1 [46235355]
—
2.3e+00
—
—
—
2.3e+00
9.0e-01
—
—
cases:12.35%
controls:1.36%
—
—
—
—
—
—
cases:12.33%
controls:1.37%
cases:13.04%
controls:5.76%
—
10
11
71
796
—
—
—
9
11
64
791
9
43
60
704
felodipine; oral
C08CA02 [21601748]
C08CA02 [21601748]
2.1e+00
—
—
—
—
2.5e+00
—
cases:7.69%
controls:1.03%
—
—
—
—
—
—
—
—
cases:8.22%
controls:0.75%
—
—
6
8
72
771
—
—
—
—
6
6
67
796
—
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
5195-3 [3019284]
8.6e-01
2.3e+00
—
—
—
2.2e+00
1.1e+00
cases:6.41%
controls:2.82%
cases:12.35%
controls:1.36%
—
—
—
—
—
—
cases:12.33%
controls:1.50%
cases:11.59%
controls:4.28%
5
22
73
757
10
11
71
796
—
—
—
9
12
64
790
8
32
61
715
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
—
1.5e+00
—
—
3.0e+00
9.8e-01
8.1e-01
—
—
cases:12.35%
controls:3.10%
—
—
—
—
cases:11.69%
controls:0.62%
cases:12.33%
controls:4.99%
cases:27.54%
controls:14.46%
—
10
25
71
782
—
—
9
5
68
802
9
40
64
762
19
108
50
639
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
—
1.5e+00
—
—
3.0e+00
1.0e+00
8.7e-01
—
—
cases:12.35%
controls:3.10%
—
—
—
—
cases:11.69%
controls:0.62%
cases:12.33%
controls:4.86%
cases:28.99%
controls:14.59%
—
10
25
71
782
—
—
9
5
68
802
9
39
64
763
20
109
49
638
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
—
1.5e+00
—
—
3.0e+00
1.0e+00
8.1e-01
—
—
cases:12.35%
controls:3.10%
—
—
—
—
cases:11.69%
controls:0.62%
cases:12.33%
controls:4.86%
cases:27.54%
controls:14.46%
—
10
25
71
782
—
—
9
5
68
802
9
39
64
763
19
108
50
639
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
16128-1 [3017143]
1.4e+00
—
—
—
—
2.5e+00
1.9e+00
cases:6.41%
controls:1.67%
—
—
—
—
—
—
—
—
cases:12.33%
controls:1.12%
cases:11.59%
controls:2.01%
5
13
73
766
—
—
—
—
9
9
64
793
8
15
61
732
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
1.1e+00
1.1e+00
—
—
—
2.4e+00
1.9e+00
cases:11.54%
controls:3.98%
cases:6.17%
controls:2.11%
—
—
—
—
—
—
cases:12.33%
controls:1.25%
cases:20.29%
controls:3.48%
9
31
69
748
5
17
76
790
—
—
—
9
10
64
792
14
26
55
721
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
2705-2 [3024354]
—
—
—
—
—
2.3e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:8.22%
controls:0.87%
cases:17.39%
controls:2.95%
—
—
—
—
—
6
7
67
795
12
22
57
725
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
5.7e-01
9.6e-01
1.7e+00
—
2.8e+00
1.4e+00
8.2e-01
cases:7.69%
controls:4.49%
cases:7.41%
controls:2.97%
cases:6.17%
controls:1.24%
—
—
cases:14.29%
controls:0.99%
cases:13.70%
controls:3.62%
cases:18.84%
controls:9.24%
6
35
72
744
6
24
75
783
5
10
76
797
—
11
8
66
799
10
29
63
773
13
69
56
678
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
-6.9e-02
6.9e-01
1.7e+00
1.0e+50
2.5e+00
8.2e-01
7.6e-01
cases:10.26%
controls:10.91%
cases:14.81%
controls:8.05%
cases:16.05%
controls:3.22%
cases:7.41%
controls:0.00%
cases:18.18%
controls:1.86%
cases:17.81%
controls:8.73%
cases:36.23%
controls:21.02%
8
85
70
694
12
65
69
742
13
26
68
781
6
0
75
807
14
15
63
792
13
70
60
732
25
157
44
590
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
—
2.1e+00
—
—
—
2.0e+00
6.6e-01
—
—
cases:7.41%
controls:0.99%
—
—
—
—
—
—
cases:9.59%
controls:1.37%
cases:10.14%
controls:5.49%
—
6
8
75
799
—
—
—
7
11
66
791
7
41
62
706
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
32294-1 [3020682]
8.1e-01
1.3e+00
2.7e+00
—
—
1.6e+00
1.4e+00
cases:6.41%
controls:2.95%
cases:7.41%
controls:2.23%
cases:9.88%
controls:0.74%
—
—
—
—
cases:9.59%
controls:2.00%
cases:23.19%
controls:6.83%
5
23
73
756
6
18
75
789
8
6
73
801
—
—
7
16
66
786
16
51
53
696
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
6.6e-01
—
—
—
—
2.5e+00
1.5e+00
cases:7.69%
controls:4.11%
—
—
—
—
—
—
—
—
cases:13.70%
controls:1.25%
cases:14.49%
controls:3.48%
6
32
72
747
—
—
—
—
10
10
63
792
10
26
59
721
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
-4.3e-02
1.0e+00
—
1.0e+50
3.0e+00
1.1e+00
9.9e-01
cases:10.26%
controls:10.65%
cases:16.05%
controls:6.44%
—
—
cases:8.64%
controls:0.00%
cases:16.88%
controls:0.99%
cases:19.18%
controls:7.48%
cases:36.23%
controls:17.40%
8
83
70
696
13
52
68
755
—
7
0
74
807
13
8
64
799
14
60
59
742
25
130
44
617
Urgent procedure
ZXD05 [2001311386]
ZXD05 [2001311386]
4.6e-01
—
—
1.0e+50
—
2.1e+00
1.9e+00
cases:7.69%
controls:5.01%
—
—
—
—
cases:6.17%
controls:0.00%
—
—
cases:8.22%
controls:1.12%
cases:17.39%
controls:3.08%
6
39
72
740
—
—
5
0
76
807
—
6
9
67
793
12
23
57
724
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
51485-1 [3030306]
—
—
1.0e+50
—
—
2.1e+00
1.8e+00
—
—
—
—
cases:6.17%
controls:0.00%
—
—
—
—
cases:12.33%
controls:1.62%
cases:20.29%
controls:4.02%
—
—
5
0
76
807
—
—
9
13
64
789
14
30
55
717
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
-4.1e-01
3.6e-01
1.5e+00
—
2.4e+00
8.6e-01
5.7e-01
cases:12.82%
controls:18.10%
cases:20.99%
controls:15.61%
cases:20.99%
controls:5.70%
—
—
cases:31.17%
controls:3.97%
cases:32.88%
controls:17.21%
cases:46.38%
controls:32.80%
10
141
68
638
17
126
64
681
17
46
64
761
—
24
32
53
775
24
138
49
664
32
245
37
502
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
-1.2e-01
2.3e-01
1.5e+00
—
2.3e+00
8.8e-01
4.7e-01
cases:16.67%
controls:18.36%
cases:17.28%
controls:14.25%
cases:17.28%
controls:4.34%
—
—
cases:24.68%
controls:3.22%
cases:26.03%
controls:12.72%
cases:40.58%
controls:29.85%
13
143
65
636
14
115
67
692
14
35
67
772
—
19
26
58
781
19
102
54
700
28
223
41
524
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
8.7e-02
1.0e+00
1.7e+00
1.0e+50
2.6e+00
1.3e+00
1.2e+00
cases:6.41%
controls:5.91%
cases:11.11%
controls:4.34%
cases:7.41%
controls:1.49%
cases:8.64%
controls:0.00%
cases:16.88%
controls:1.49%
cases:15.07%
controls:4.74%
cases:24.64%
controls:9.10%
5
46
73
733
9
35
72
772
6
12
75
795
7
0
74
807
13
12
64
795
11
38
62
764
17
68
52
679
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
8.8e-01
1.3e+00
—
—
—
2.3e+00
1.5e+00
cases:7.69%
controls:3.34%
cases:6.17%
controls:1.73%
—
—
—
—
—
—
cases:12.33%
controls:1.37%
cases:14.49%
controls:3.75%
6
26
72
753
5
14
76
793
—
—
—
9
11
64
791
10
28
59
719
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
68438-1 [40771025]
—
4.3e-01
—
—
2.1e+00
2.1e+00
1.7e+00
—
—
cases:6.17%
controls:4.09%
—
—
—
—
cases:6.49%
controls:0.87%
cases:23.29%
controls:3.74%
cases:31.88%
controls:8.17%
—
5
33
76
774
—
—
5
7
72
800
17
30
56
772
22
61
47
686
Outpatient Hospital
22 [8756]
22 [8756]
5.0e-01
8.4e-01
1.8e+00
1.0e+50
2.3e+00
1.4e+00
7.3e-01
cases:37.18%
controls:26.44%
cases:17.28%
controls:8.30%
cases:8.64%
controls:1.61%
cases:23.46%
controls:0.00%
cases:16.88%
controls:1.98%
cases:24.66%
controls:7.48%
cases:36.23%
controls:21.42%
29
206
49
573
14
67
67
740
7
13
74
794
19
0
62
807
13
16
64
791
18
60
55
742
25
160
44
587
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
—
—
1.0e+50
—
—
1.9e+00
1.7e+00
—
—
—
—
cases:6.17%
controls:0.00%
—
—
—
—
cases:10.96%
controls:1.75%
cases:18.84%
controls:4.02%
—
—
5
0
76
807
—
—
8
14
65
788
13
30
56
717
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
3.3e-01
1.9e+00
—
—
—
1.7e+00
1.1e+00
cases:7.69%
controls:5.65%
cases:11.11%
controls:1.86%
—
—
—
—
—
—
cases:10.96%
controls:2.12%
cases:17.39%
controls:6.29%
6
44
72
735
9
15
72
792
—
—
—
8
17
65
785
12
47
57
700
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
-2.4e-01
3.9e-01
1.5e+00
—
2.1e+00
7.8e-01
3.7e-01
cases:14.10%
controls:17.20%
cases:18.52%
controls:13.38%
cases:17.28%
controls:4.58%
—
—
cases:23.38%
controls:3.59%
cases:27.40%
controls:14.71%
cases:40.58%
controls:32.13%
11
134
67
645
15
108
66
699
14
37
67
770
—
18
29
59
778
20
118
53
684
28
240
41
507
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
N02AX02 [21604298]
2.1e-01
1.9e+00
—
—
—
1.5e+00
1.6e+00
cases:6.41%
controls:5.26%
cases:9.88%
controls:1.61%
—
—
—
—
—
—
cases:8.22%
controls:1.87%
cases:18.84%
controls:4.28%
5
41
73
738
8
13
73
794
—
—
—
6
15
67
787
13
32
56
715
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
14683-7 [3009508]
6.8e-01
9.2e-01
—
—
—
1.8e+00
1.6e+00
cases:6.41%
controls:3.34%
cases:7.41%
controls:3.10%
—
—
—
—
—
—
cases:15.07%
controls:2.74%
cases:30.43%
controls:8.30%
5
26
73
753
6
25
75
782
—
—
—
11
22
62
780
21
62
48
685
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
9.2e-02
8.8e-01
—
—
3.3e+00
1.3e+00
9.2e-01
cases:7.69%
controls:7.06%
cases:9.88%
controls:4.34%
—
—
—
—
cases:16.88%
controls:0.74%
cases:9.59%
controls:2.87%
cases:26.09%
controls:12.32%
6
55
72
724
8
35
73
772
—
—
13
6
64
801
7
23
66
779
18
92
51
655
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
-1.4e-01
3.0e-01
1.2e+00
—
2.1e+00
7.3e-01
3.5e-01
cases:15.38%
controls:17.33%
cases:19.75%
controls:15.37%
cases:16.05%
controls:5.70%
—
—
cases:25.97%
controls:4.21%
cases:27.40%
controls:15.34%
cases:37.68%
controls:29.85%
12
135
66
644
16
124
65
683
13
46
68
761
—
20
34
57
773
20
123
53
679
26
223
43
524
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
-2.8e-01
1.2e-01
1.2e+00
—
2.0e+00
6.5e-01
4.0e-01
cases:17.95%
controls:22.46%
cases:22.22%
controls:20.20%
cases:22.22%
controls:7.68%
—
—
cases:29.87%
controls:5.70%
cases:34.25%
controls:21.32%
cases:47.83%
controls:38.02%
14
175
64
604
18
163
63
644
18
62
63
745
—
23
46
54
761
25
171
48
631
33
284
36
463
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
72720-6 [43055554]
—
—
—
—
3.2e+00
1.6e+00
1.2e+00
—
—
—
—
—
—
—
—
cases:12.99%
controls:0.62%
cases:6.85%
controls:1.50%
cases:7.25%
controls:2.28%
—
—
—
—
10
5
67
802
5
12
68
790
5
17
64
730
pH of Capillary blood
2745-8 [3009343]
2745-8 [3009343]
—
—
—
—
3.2e+00
1.6e+00
1.2e+00
—
—
—
—
—
—
—
—
cases:12.99%
controls:0.62%
cases:6.85%
controls:1.50%
cases:7.25%
controls:2.28%
—
—
—
—
10
5
67
802
5
12
68
790
5
17
64
730
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
2020-6 [3023024]
—
—
—
—
3.2e+00
1.6e+00
1.3e+00
—
—
—
—
—
—
—
—
cases:12.99%
controls:0.62%
cases:6.85%
controls:1.50%
cases:8.70%
controls:2.54%
—
—
—
—
10
5
67
802
5
12
68
790
6
19
63
728
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
2704-5 [3028626]
—
—
—
—
3.2e+00
1.8e+00
—
—
—
—
—
—
—
—
—
cases:12.99%
controls:0.62%
cases:6.85%
controls:1.25%
—
—
—
—
—
—
10
5
67
802
5
10
68
792
—
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
-2.7e-01
1.2e-01
1.2e+00
—
2.0e+00
6.6e-01
4.0e-01
cases:17.95%
controls:22.34%
cases:22.22%
controls:20.20%
cases:20.99%
controls:7.68%
—
—
cases:29.87%
controls:5.70%
cases:34.25%
controls:21.20%
cases:47.83%
controls:38.02%
14
174
64
605
18
163
63
644
17
62
64
745
—
23
46
54
761
25
170
48
632
33
284
36
463
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
-2.7e-01
1.2e-01
1.2e+00
—
2.0e+00
6.5e-01
4.0e-01
cases:17.95%
controls:22.34%
cases:22.22%
controls:20.20%
cases:20.99%
controls:7.68%
—
—
cases:29.87%
controls:5.70%
cases:34.25%
controls:21.32%
cases:47.83%
controls:38.02%
14
174
64
605
18
163
63
644
17
62
64
745
—
23
46
54
761
25
171
48
631
33
284
36
463
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
-2.8e-01
1.2e-01
1.2e+00
—
2.0e+00
6.5e-01
4.0e-01
cases:17.95%
controls:22.46%
cases:22.22%
controls:20.20%
cases:20.99%
controls:7.68%
—
—
cases:29.87%
controls:5.70%
cases:34.25%
controls:21.32%
cases:47.83%
controls:38.02%
14
175
64
604
18
163
63
644
17
62
64
745
—
23
46
54
761
25
171
48
631
33
284
36
463
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
-2.8e-01
1.2e-01
1.2e+00
—
2.0e+00
6.4e-01
4.0e-01
cases:17.95%
controls:22.46%
cases:22.22%
controls:20.20%
cases:20.99%
controls:7.68%
—
—
cases:29.87%
controls:5.70%
cases:34.25%
controls:21.57%
cases:47.83%
controls:38.02%
14
175
64
604
18
163
63
644
17
62
64
745
—
23
46
54
761
25
173
48
629
33
284
36
463
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
-2.8e-01
1.2e-01
1.2e+00
—
2.0e+00
6.5e-01
4.0e-01
cases:17.95%
controls:22.46%
cases:22.22%
controls:20.20%
cases:20.99%
controls:7.68%
—
—
cases:29.87%
controls:5.70%
cases:34.25%
controls:21.32%
cases:47.83%
controls:38.02%
14
175
64
604
18
163
63
644
17
62
64
745
—
23
46
54
761
25
171
48
631
33
284
36
463
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
-3.0e-01
1.1e-01
1.2e+00
—
1.9e+00
6.5e-01
3.8e-01
cases:17.95%
controls:22.72%
cases:22.22%
controls:20.32%
cases:20.99%
controls:7.68%
—
—
cases:29.87%
controls:5.82%
cases:34.25%
controls:21.45%
cases:47.83%
controls:38.42%
14
177
64
602
18
164
63
643
17
62
64
745
—
23
47
54
760
25
172
48
630
33
287
36
460
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
4.5e-01
2.6e-01
7.0e-01
3.0e+00
6.9e-01
5.5e-01
1.4e-01
cases:60.26%
controls:49.17%
cases:49.38%
controls:42.87%
cases:29.63%
controls:17.22%
cases:17.28%
controls:0.99%
cases:31.17%
controls:18.46%
cases:60.27%
controls:46.76%
cases:71.01%
controls:68.01%
47
383
31
396
40
346
41
461
24
139
57
668
14
8
67
799
24
149
53
658
44
375
29
427
49
508
20
239
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
1.3e+00
1.7e+00
—
—
—
7.8e-01
7.8e-01
cases:16.67%
controls:5.26%
cases:9.88%
controls:1.98%
—
—
—
—
—
—
cases:6.85%
controls:3.24%
cases:15.94%
controls:8.03%
13
41
65
738
8
16
73
791
—
—
—
5
26
68
776
11
60
58
687
Chronic kidney disease, unspecified
N18.9 [45553438]
N18.9 [45553438]
—
1.0e+50
—
—
1.0e+50
—
3.0e+00
—
—
cases:11.11%
controls:0.00%
—
—
—
—
cases:7.79%
controls:0.00%
—
—
cases:17.39%
controls:1.07%
—
9
0
72
807
—
—
6
0
71
807
—
12
8
57
739
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
—
—
—
1.0e+50
—
—
2.8e+00
—
—
—
—
—
—
cases:7.41%
controls:0.00%
—
—
—
—
cases:23.19%
controls:1.74%
—
—
—
6
0
75
807
—
—
16
13
53
734
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
-3.2e-02
8.5e-01
—
—
2.7e+00
8.1e-01
3.7e-01
cases:8.97%
controls:9.24%
cases:11.11%
controls:5.08%
—
—
—
—
cases:11.69%
controls:0.87%
cases:13.70%
controls:6.61%
cases:21.74%
controls:16.06%
7
72
71
707
9
41
72
766
—
—
9
7
68
800
10
53
63
749
15
120
54
627
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
-3.4e-01
2.1e-01
1.1e+00
—
1.6e+00
3.0e-01
2.1e-01
cases:20.51%
controls:26.57%
cases:30.86%
controls:26.52%
cases:25.93%
controls:10.29%
—
—
cases:32.47%
controls:8.92%
cases:34.25%
controls:27.81%
cases:49.28%
controls:44.18%
16
207
62
572
25
214
56
593
21
83
60
724
—
25
72
52
735
25
223
48
579
34
330
35
417
Protein [Mass/volume] in Urine
2888-6 [3037121]
2888-6 [3037121]
-1.0e+50
—
—
—
—
2.1e+00
2.6e+00
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:6.85%
controls:0.87%
cases:10.14%
controls:0.80%
0
5
78
774
—
—
—
—
5
7
68
795
7
6
62
741
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.04%
controls:1.07%
—
—
—
—
—
—
9
8
60
739
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
—
1.5e+00
—
—
2.6e+00
—
8.7e-01
—
—
cases:6.17%
controls:1.49%
—
—
—
—
cases:7.79%
controls:0.62%
—
—
cases:11.59%
controls:5.22%
—
5
12
76
795
—
—
6
5
71
802
—
8
39
61
708
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
4.7e-01
1.6e+00
2.5e+00
—
—
1.5e+00
1.2e+00
cases:6.41%
controls:4.11%
cases:9.88%
controls:2.23%
cases:7.41%
controls:0.62%
—
—
—
—
cases:9.59%
controls:2.24%
cases:14.49%
controls:4.82%
5
32
73
747
8
18
73
789
6
5
75
802
—
—
7
18
66
784
10
36
59
711
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
14927-8 [3025839]
2.5e+00
—
—
—
—
2.1e+00
7.1e-01
cases:8.97%
controls:0.77%
—
—
—
—
—
—
—
—
cases:6.85%
controls:0.87%
cases:11.59%
controls:6.02%
7
6
71
773
—
—
—
—
5
7
68
795
8
45
61
702
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
1.1e+00
2.5e+00
—
—
—
—
1.0e+00
cases:7.69%
controls:2.57%
cases:9.88%
controls:0.87%
—
—
—
—
—
—
—
—
cases:8.70%
controls:3.35%
6
20
72
759
8
7
73
800
—
—
—
—
6
25
63
722
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
1.0e+00
—
—
—
—
1.6e+00
2.5e+00
cases:6.41%
controls:2.44%
—
—
—
—
—
—
—
—
cases:8.22%
controls:1.75%
cases:20.29%
controls:2.01%
5
19
73
760
—
—
—
—
6
14
67
788
14
15
55
732
Standard cardiac ultrasound examination
FM1AE [2001303278]
FM1AE [2001303278]
—
1.7e+00
—
—
—
2.5e+00
1.6e+00
—
—
cases:6.17%
controls:1.24%
—
—
—
—
—
—
cases:9.59%
controls:0.87%
cases:11.59%
controls:2.68%
—
5
10
76
797
—
—
—
7
7
66
795
8
20
61
727
More than three and less than five hours
ZXE20 [2001311408]
ZXE20 [2001311408]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.14%
controls:0.94%
—
—
—
—
—
—
7
7
62
740
General Surgery
2 [38004447]
2 [38004447]
6.7e-01
4.5e-01
—
1.0e+50
2.4e+00
9.6e-01
8.7e-01
cases:29.49%
controls:17.59%
cases:8.64%
controls:5.70%
—
—
cases:7.41%
controls:0.00%
cases:9.09%
controls:0.87%
cases:10.96%
controls:4.49%
cases:27.54%
controls:13.79%
23
137
55
642
7
46
74
761
—
6
0
75
807
7
7
70
800
8
36
65
766
19
103
50
644
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
—
2.0e+00
—
—
—
2.4e+00
1.1e+00
—
—
cases:7.41%
controls:1.12%
—
—
—
—
—
—
cases:12.33%
controls:1.25%
cases:8.70%
controls:3.08%
—
6
9
75
798
—
—
—
9
10
64
792
6
23
63
724
amoxicillin; oral, parenteral
J01CA04 [21602823]
J01CA04 [21602823]
4.9e-01
8.1e-01
—
—
—
1.3e+00
1.1e+00
cases:35.90%
controls:25.55%
cases:16.05%
controls:7.81%
—
—
—
—
—
—
cases:19.18%
controls:5.99%
cases:43.48%
controls:21.15%
28
199
50
580
13
63
68
744
—
—
—
14
48
59
754
30
158
39
589
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
—
1.5e+00
2.4e+00
—
—
1.5e+00
4.3e-01
—
—
cases:7.41%
controls:1.73%
cases:7.41%
controls:0.74%
—
—
—
—
cases:9.59%
controls:2.37%
cases:10.14%
controls:6.83%
—
6
14
75
793
6
6
75
801
—
—
7
19
66
783
7
51
62
696
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
29953-7 [3037522]
—
2.4e+00
—
—
—
—
—
—
—
cases:7.41%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
6
6
75
801
—
—
—
—
—
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
NA3AA [2001307026]
2.4e+00
—
—
—
—
—
—
cases:6.41%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
73
774
—
—
—
—
—
—
azathioprine; oral, parenteral
L04AX01 [21603927]
L04AX01 [21603927]
2.4e+00
—
—
—
—
—
-1.0e+50
cases:6.41%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
5
5
73
774
—
—
—
—
—
0
8
69
739
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
—
1.8e+00
—
—
—
2.3e+00
1.3e+00
—
—
cases:7.41%
controls:1.36%
—
—
—
—
—
—
cases:9.59%
controls:1.00%
cases:13.04%
controls:3.88%
—
6
11
75
796
—
—
—
7
8
66
794
9
29
60
718
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
2.7e-02
9.6e-01
1.8e+00
1.0e+50
2.3e+00
7.5e-01
8.8e-01
cases:10.26%
controls:10.01%
cases:13.58%
controls:5.70%
cases:6.17%
controls:1.12%
cases:6.17%
controls:0.00%
cases:9.09%
controls:0.99%
cases:12.33%
controls:6.23%
cases:30.43%
controls:15.39%
8
78
70
701
11
46
70
761
5
9
76
798
5
0
76
807
7
8
70
799
9
50
64
752
21
115
48
632
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
—
2.2e+00
—
—
—
—
—
—
—
cases:8.64%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
7
8
74
799
—
—
—
—
—
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
2.2e+00
—
—
—
—
—
—
cases:7.69%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
72
772
—
—
—
—
—
—
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
—
1.2e+00
—
—
—
2.1e+00
7.2e-01
—
—
cases:6.17%
controls:1.98%
—
—
—
—
—
—
cases:12.33%
controls:1.62%
cases:10.14%
controls:5.22%
—
5
16
76
791
—
—
—
9
13
64
789
7
39
62
708
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
72160-5 [43054903]
7.7e-01
2.1e+00
—
—
—
1.7e+00
3.9e-01
cases:6.41%
controls:3.08%
cases:8.64%
controls:1.12%
—
—
—
—
—
—
cases:6.85%
controls:1.37%
cases:10.14%
controls:7.10%
5
24
73
755
7
9
74
798
—
—
—
5
11
68
791
7
53
62
694
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1963-8 [3016293]
-1.0e+50
—
—
—
—
1.9e+00
2.1e+00
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
cases:8.22%
controls:1.37%
cases:15.94%
controls:2.28%
0
11
78
768
—
—
—
—
6
11
67
791
11
17
58
730
clopidogrel; oral
B01AC04 [21600989]
B01AC04 [21600989]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.70%
controls:1.20%
—
—
—
—
—
—
6
9
63
738
Cardiology
6 [38004451]
6 [38004451]
2.8e-01
8.1e-01
2.2e+00
—
—
2.0e+00
8.1e-01
cases:8.97%
controls:6.93%
cases:6.17%
controls:2.85%
cases:6.17%
controls:0.74%
—
—
—
—
cases:17.81%
controls:2.87%
cases:15.94%
controls:7.76%
7
54
71
725
5
23
76
784
5
6
76
801
—
—
13
23
60
779
11
58
58
689
prednisone; oral
H02AB07 [21602735]
H02AB07 [21602735]
2.0e+00
—
—
—
—
—
—
cases:10.26%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
—
8
12
70
767
—
—
—
—
—
—
prednisone
A07EA03 [21600655]
A07EA03 [21600655]
2.0e+00
—
—
—
—
—
—
cases:10.26%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
—
8
12
70
767
—
—
—
—
—
—
Obstetrics / Gynecology
16 [38004461]
16 [38004461]
-4.4e-01
7.4e-01
1.8e+00
—
2.0e+00
4.1e-01
-2.9e-02
cases:10.26%
controls:15.02%
cases:12.35%
controls:6.32%
cases:7.41%
controls:1.36%
—
—
cases:9.09%
controls:1.36%
cases:8.22%
controls:5.61%
cases:15.94%
controls:16.33%
8
117
70
662
10
51
71
756
6
11
75
796
—
7
11
70
796
6
45
67
757
11
122
58
625
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
1.8e+00
—
—
—
—
—
1.9e+00
cases:6.41%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
cases:10.14%
controls:1.61%
5
9
73
770
—
—
—
—
—
7
12
62
735
Medical Oncology
90 [38004507]
90 [38004507]
1.6e+00
1.9e+00
—
—
—
—
—
cases:7.69%
controls:1.67%
cases:8.64%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
6
13
72
766
7
11
74
796
—
—
—
—
—
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
6.6e-01
—
—
—
—
—
1.8e+00
cases:7.69%
controls:4.11%
—
—
—
—
—
—
—
—
—
—
cases:23.19%
controls:4.55%
6
32
72
747
—
—
—
—
—
16
34
53
713
Bilateral
ZXA10 [2001311348]
ZXA10 [2001311348]
1.8e+00
—
—
—
—
-1.0e+50
—
cases:8.97%
controls:1.54%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
7
12
71
767
—
—
—
—
0
6
73
796
—
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
—
1.8e+00
—
1.0e+50
1.0e+50
—
7.6e-01
—
—
cases:8.64%
controls:1.49%
—
—
cases:7.41%
controls:0.00%
cases:6.49%
controls:0.00%
—
—
cases:14.49%
controls:7.36%
—
7
12
74
795
—
6
0
75
807
5
0
72
807
—
10
55
59
692
omeprazole; oral, parenteral
A02BC01 [21600096]
A02BC01 [21600096]
9.3e-01
1.8e+00
—
—
—
1.6e+00
6.6e-01
cases:8.97%
controls:3.72%
cases:8.64%
controls:1.49%
—
—
—
—
—
—
cases:6.85%
controls:1.50%
cases:7.25%
controls:3.88%
7
29
71
750
7
12
74
795
—
—
—
5
12
68
790
5
29
64
718
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
—
1.6e+00
—
—
—
1.7e+00
1.8e+00
—
—
cases:8.64%
controls:1.86%
—
—
—
—
—
—
cases:6.85%
controls:1.37%
cases:17.39%
controls:3.48%
—
7
15
74
792
—
—
—
5
11
68
791
12
26
57
721
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
1.0e+00
—
—
—
—
—
1.7e+00
cases:10.26%
controls:3.98%
—
—
—
—
—
—
—
—
—
—
cases:14.49%
controls:2.95%
8
31
70
748
—
—
—
—
—
10
22
59
725
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
1.3e-01
1.7e+00
—
—
—
—
6.8e-01
cases:6.41%
controls:5.65%
cases:13.58%
controls:2.85%
—
—
—
—
—
—
—
—
cases:14.49%
controls:7.90%
5
44
73
735
11
23
70
784
—
—
—
—
10
59
59
688
Albumin [Mass/volume] in Urine
1754-1 [3012516]
1754-1 [3012516]
—
1.3e+00
—
—
—
1.6e+00
1.5e+00
—
—
cases:7.41%
controls:2.11%
—
—
—
—
—
—
cases:9.59%
controls:2.00%
cases:24.64%
controls:6.69%
—
6
17
75
790
—
—
—
7
16
66
786
17
50
52
697
Pediatric Medicine
37 [38004477]
37 [38004477]
—
—
—
—
1.5e+00
4.3e-01
5.0e-01
—
—
—
—
—
—
—
—
cases:14.29%
controls:3.59%
cases:12.33%
controls:8.35%
cases:15.94%
controls:10.31%
—
—
—
—
11
29
66
778
9
67
64
735
11
77
58
670
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
8.5e-01
5.7e-01
-1.0e+50
—
—
1.5e+00
5.3e-01
cases:19.23%
controls:9.24%
cases:6.17%
controls:3.59%
cases:0.00%
controls:0.62%
—
—
—
—
cases:13.70%
controls:3.49%
cases:14.49%
controls:9.10%
15
72
63
707
5
29
76
778
0
5
81
802
—
—
10
28
63
774
10
68
59
679
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
—
1.4e+00
—
—
—
1.2e+00
1.4e+00
—
—
cases:6.17%
controls:1.61%
—
—
—
—
—
—
cases:6.85%
controls:2.12%
cases:17.39%
controls:4.95%
—
5
13
76
794
—
—
—
5
17
68
785
12
37
57
710
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
9.6e-01
8.0e-01
—
1.0e+50
—
1.3e+00
7.4e-01
cases:20.51%
controls:8.99%
cases:7.41%
controls:3.47%
—
—
cases:8.64%
controls:0.00%
—
—
cases:16.44%
controls:4.99%
cases:24.64%
controls:13.52%
16
70
62
709
6
28
75
779
—
7
0
74
807
—
12
40
61
762
17
101
52
646
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
-2.1e-01
3.9e-01
7.8e-01
-1.0e+50
1.2e+00
7.1e-01
-5.8e-02
cases:89.74%
controls:91.53%
cases:83.95%
controls:77.94%
cases:56.79%
controls:37.67%
cases:0.00%
controls:2.23%
cases:68.83%
controls:38.79%
cases:87.67%
controls:77.68%
cases:94.20%
controls:94.51%
70
713
8
66
68
629
13
178
46
304
35
503
0
18
81
789
53
313
24
494
64
623
9
179
65
706
4
41
atorvastatin; oral
C10AA05 [21601860]
C10AA05 [21601860]
8.7e-01
—
—
—
—
1.1e+00
1.2e+00
cases:8.97%
controls:3.98%
—
—
—
—
—
—
—
—
cases:12.33%
controls:4.49%
cases:21.74%
controls:7.63%
7
31
71
748
—
—
—
—
9
36
64
766
15
57
54
690
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
3.8e-01
7.3e-01
—
—
2.1e+00
1.0e+00
1.2e+00
cases:6.41%
controls:4.49%
cases:7.41%
controls:3.72%
—
—
—
—
cases:6.49%
controls:0.87%
cases:8.22%
controls:3.12%
cases:18.84%
controls:6.83%
5
35
73
744
6
30
75
777
—
—
5
7
72
800
6
25
67
777
13
51
56
696
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
20454-5 [3014051]
-1.0e+50
—
—
—
—
—
1.1e+00
cases:0.00%
controls:2.05%
—
—
—
—
—
—
—
—
—
—
cases:21.74%
controls:8.43%
0
16
78
763
—
—
—
—
—
15
63
54
684
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
14646-4 [3023602]
4.1e-01
4.6e-01
—
—
—
1.0e+00
4.8e-01
cases:16.67%
controls:11.68%
cases:11.11%
controls:7.31%
—
—
—
—
—
—
cases:21.92%
controls:8.98%
cases:34.78%
controls:24.90%
13
91
65
688
9
59
72
748
—
—
—
16
72
57
730
24
186
45
561
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
1.7e-02
4.0e-01
—
—
—
1.0e+00
1.0e+00
cases:7.69%
controls:7.57%
cases:6.17%
controls:4.21%
—
—
—
—
—
—
cases:9.59%
controls:3.62%
cases:27.54%
controls:11.78%
6
59
72
720
5
34
76
773
—
—
—
7
29
66
773
19
88
50
659
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
—
1.1e+00
—
—
—
6.4e-01
1.0e+00
—
—
cases:7.41%
controls:2.48%
—
—
—
—
—
—
cases:6.85%
controls:3.74%
cases:27.54%
controls:12.18%
—
6
20
75
787
—
—
—
5
30
68
772
19
91
50
656
Other hypothyroidism
E03 [45581337]
E03 [45581337]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
69
742
False labour before 37 completed weeks of gestation
O47.0 [45582556]
O47.0 [45582556]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.94%
0
12
78
767
—
—
—
—
0
6
73
796
0
7
69
740
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
C01DA02 [21600317]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:2.60%
—
—
—
—
—
—
cases:0.00%
controls:3.12%
—
—
—
0
21
81
786
—
—
—
0
25
73
777
—
Choriogonadotropin [Units/volume] in Urine
25372-4 [3023511]
25372-4 [3023511]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
6
69
741
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
12841-3 [3001784]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.41%
cases:0.00%
controls:1.24%
—
—
—
—
—
—
—
—
—
—
0
11
78
768
0
10
81
797
—
—
—
—
—
fluticasone; nasal
R01AD08 [21605050]
R01AD08 [21605050]
2.4e-01
—
—
—
—
—
1.4e-01
cases:8.97%
controls:7.19%
—
—
—
—
—
—
—
—
—
—
cases:8.70%
controls:7.63%
7
56
71
723
—
—
—
—
—
6
57
63
690
Knee symptom/complaint
L15 [2002000639]
L15 [2002000639]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
0
7
81
800
—
—
—
0
8
73
794
—
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
6357-8 [3024950]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
—
0
7
73
795
—
Extensive abdominal CT
JN3BD [2001305556]
JN3BD [2001305556]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
7
69
740
Helicobacter pylori Ab [Units/volume] in Serum
7900-4 [3017895]
7900-4 [3017895]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
6
69
741
Migraine with aura [classical migraine]
G43.1 [45562086]
G43.1 [45562086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
78
774
—
—
—
—
—
—
Blasts/Leukocytes in Blood
26446-5 [3025159]
26446-5 [3025159]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:6.49%
controls:0.00%
—
—
—
—
—
—
—
—
5
0
72
807
—
—
Deposits [accretions] on teeth betel
K03.65 [2000502690]
K03.65 [2000502690]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.08%
0
14
78
765
—
—
—
—
—
0
23
69
724
Reagin Ab [Titer] in Serum by VDRL
50690-7 [3029634]
50690-7 [3029634]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:6.85%
controls:0.00%
—
—
—
—
—
—
—
5
0
68
802
—
warfarin; oral, parenteral
B01AA03 [21600965]
B01AA03 [21600965]
—
—
-1.0e+50
—
-1.0e+50
—
5.6e-01
—
—
—
—
cases:0.00%
controls:0.74%
—
—
cases:0.00%
controls:0.74%
—
—
cases:7.25%
controls:4.28%
—
—
0
6
81
801
—
0
6
77
801
—
5
32
64
715
Hallux valgus (acquired)
M20.1 [45606152]
M20.1 [45606152]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
78
774
—
—
—
—
—
—
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
M03BC01 [21604112]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
—
0
14
81
793
—
—
—
—
—
Body height measure
50373000 [4177340]
50373000 [4177340]
-1.1e+00
—
—
—
—
1.0e+50
1.0e+50
cases:10.26%
controls:25.80%
—
—
—
—
—
—
—
—
cases:6.85%
controls:0.00%
cases:13.04%
controls:0.00%
8
201
70
578
—
—
—
—
5
0
68
802
9
0
60
747
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
J07BA01 [21601331]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
5
73
797
—
combinations of corticosteroids
D07XB30 [21602188]
D07XB30 [21602188]
-1.7e-02
—
—
—
—
—
-8.8e-02
cases:8.97%
controls:9.11%
—
—
—
—
—
—
—
—
—
—
cases:10.14%
controls:10.98%
7
71
71
708
—
—
—
—
—
7
82
62
665
gabapentin; oral
N02BF01 [955005]
N02BF01 [955005]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
0
6
73
796
—
orphenadrine, combinations
M03BC51 [21604113]
M03BC51 [21604113]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.82%
cases:0.00%
controls:0.87%
—
—
—
—
—
—
—
—
—
—
0
22
78
757
0
7
81
800
—
—
—
—
—
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
—
-1.0e+50
—
—
—
—
4.6e-01
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
cases:7.25%
controls:4.69%
—
0
14
81
793
—
—
—
—
5
35
64
712
Viral infection, unspecified
B34.9 [45605229]
B34.9 [45605229]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
6
69
741
Fracture of tooth, open
S02.51 [45755762]
S02.51 [45755762]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
7
69
740
norethisterone; oral
G03DC02 [21602553]
G03DC02 [21602553]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
78
768
—
—
—
—
—
—
Rheumatology
66 [38004491]
66 [38004491]
8.8e-01
—
—
—
—
—
—
cases:7.69%
controls:3.34%
—
—
—
—
—
—
—
—
—
—
—
—
6
26
72
753
—
—
—
—
—
—
Opiates [Presence] in Urine
3879-4 [3027008]
3879-4 [3027008]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.87%
—
—
—
—
—
—
0
14
69
733
Kolposcopy
ULA02 [2001306679]
ULA02 [2001306679]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
6
69
741
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
—
1.1e+00
—
—
—
—
2.6e-02
—
—
cases:7.41%
controls:2.48%
—
—
—
—
—
—
—
—
cases:10.14%
controls:9.91%
—
6
20
75
787
—
—
—
—
7
74
62
673
Stomatognathic treatment, basic
SHA02 [2001310406]
SHA02 [2001310406]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
6
69
741
Streptococcus pyogenes Ag [Presence] in Throat
18481-2 [3033319]
18481-2 [3033319]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
0
9
81
798
—
—
—
0
7
73
795
—
moxifloxacin; oral, parenteral
J01MA14 [21603021]
J01MA14 [21603021]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
78
773
—
—
—
—
—
—
Melanocytic naevi of trunk
D22.5 [45542688]
D22.5 [45542688]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
6
69
741
Dentistry
C5 [903277]
C5 [903277]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.08%
—
—
—
—
—
—
0
23
69
724
Pure hypercholesterolaemia
E78.01 [2000501514]
E78.01 [2000501514]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
78
765
—
—
—
—
—
—
HLA Ab [Presence] in Serum
44534-6 [3042733]
44534-6 [3042733]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:0.00%
—
—
—
—
—
—
5
0
64
747
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
N03AG01 [21604422]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.03%
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
0
8
78
771
0
5
81
802
—
—
—
—
0
8
69
739
Potassium [Moles/volume] in Arterial blood
32713-0 [3043409]
32713-0 [3043409]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
6
69
741
clindamycin; oral, parenteral
J01FF01 [21602985]
J01FF01 [21602985]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.59%
controls:2.54%
—
—
—
—
—
—
8
19
61
728
Contusion of knee
S80.0 [45569633]
S80.0 [45569633]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
6
69
741
Left side
ZXA05 [2001311347]
ZXA05 [2001311347]
1.5e+00
-1.0e+50
—
—
—
2.3e+00
1.2e+00
cases:8.97%
controls:2.05%
cases:0.00%
controls:0.62%
—
—
—
—
—
—
cases:6.85%
controls:0.75%
cases:10.14%
controls:3.35%
7
16
71
763
0
5
81
802
—
—
—
5
6
68
796
7
25
62
722
Acute apical periodontitis of pulpal origin
K04.4 [45567286]
K04.4 [45567286]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
9
69
738
Unspecified hemorrhoids without complication
I84.9 [45552863]
I84.9 [45552863]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
78
774
—
—
—
—
—
—
hydrochlorothiazide; oral
C03AA03 [21601466]
C03AA03 [21601466]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
0
10
73
792
—
Neurosurgery
14 [38004459]
14 [38004459]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
78
773
—
—
—
—
—
—
Supervision of normal pregnancy, unspecified
Z34.9 [45566420]
Z34.9 [45566420]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.34%
0
17
78
762
—
—
—
—
—
0
10
69
737
Breast cancer
115 [2001600115]
115 [2001600115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
78
774
—
—
—
—
—
—
Photography of skin or subcutaneous tissue in torso, unspecified
QB9S1 [2001309886]
QB9S1 [2001309886]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
0
5
81
802
—
—
—
—
—
Periodontal treatment
SDA03 [2001310328]
SDA03 [2001310328]
—
—
—
—
—
—
8.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.04%
controls:5.89%
—
—
—
—
—
—
9
44
60
703
Monitored bed care
WX892 [2001310850]
WX892 [2001310850]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
69
742
Primary gonarthrosis, bilateral
M17.0 [45562648]
M17.0 [45562648]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.01%
0
5
78
774
—
—
—
—
—
0
15
69
732
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
3209-4 [3019250]
—
—
—
—
1.0e+50
—
1.7e+00
—
—
—
—
—
—
—
—
cases:6.49%
controls:0.00%
—
—
cases:7.25%
controls:1.34%
—
—
—
—
5
0
72
807
—
5
10
64
737
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
97097-0 [36033641]
97097-0 [36033641]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
69
742
solifenacin; oral
G04BD08 [21602641]
G04BD08 [21602641]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
7
69
740
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
F32.10 [2000501980]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.28%
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
0
10
78
769
0
5
81
802
—
—
—
—
—
sotalol; oral, parenteral
C07AA07 [21601672]
C07AA07 [21601672]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
78
774
—
—
—
—
—
—
Pediatric Hematology-Oncology
OMOP4822028 [45756811]
OMOP4822028 [45756811]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.16%
cases:0.00%
controls:0.74%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.80%
0
9
78
770
0
6
81
801
—
—
—
0
6
73
796
0
6
69
741
Gingivitis (chronic) NOS
K05.10 [2000502717]
K05.10 [2000502717]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.01%
—
—
—
—
—
—
0
15
69
732
Simple extraction of IUD
TLC02 [2001306648]
TLC02 [2001306648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
69
742
Nonorganic insomnia
F51.0 [45552492]
F51.0 [45552492]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
5
78
774
—
—
—
—
0
5
73
797
—
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
1.4e+00
—
—
—
—
—
-1.0e+50
cases:7.69%
controls:1.93%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.95%
6
15
72
764
—
—
—
—
—
0
22
69
725
terbinafine; oral
D01BA02 [21601967]
D01BA02 [21601967]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
5
73
797
—
Obstetric epidural analgesia
WX307 [2001310797]
WX307 [2001310797]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.47%
—
—
—
—
—
—
0
11
69
736
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
JN1AE [2001305517]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:0.80%
—
—
—
—
—
—
5
6
64
741
Leukocyte morphology finding [Identifier] in Blood
11156-7 [3008757]
11156-7 [3008757]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
78
773
—
—
—
—
—
—
hydrocortisone aceponate
D07AC16 [21602135]
D07AC16 [21602135]
2.1e-01
8.5e-01
—
—
—
—
—
cases:10.26%
controls:8.47%
cases:6.17%
controls:2.73%
—
—
—
—
—
—
—
—
—
—
8
66
70
713
5
22
76
785
—
—
—
—
—
Teeth/gum symptom/complaint
D19 [2002000318]
D19 [2002000318]
—
-1.0e+50
—
—
—
-1.0e+50
2.2e-01
—
—
cases:0.00%
controls:1.49%
—
—
—
—
—
—
cases:0.00%
controls:2.12%
cases:7.25%
controls:5.89%
—
0
12
81
795
—
—
—
0
17
73
785
5
44
64
703
almotriptan; oral
N02CC05 [21604380]
N02CC05 [21604380]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.41%
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
0
11
78
768
0
6
81
801
—
—
—
—
—
First trimester maternal screen panel - Serum or Plasma
48798-3 [3050129]
48798-3 [3050129]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.34%
0
9
78
770
—
—
—
—
—
0
10
69
737
acetylsalicylic acid, combinations excl. psycholeptics
N02BA51 [21604320]
N02BA51 [21604320]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
cases:0.00%
controls:0.94%
—
0
6
81
801
—
—
—
0
8
73
794
0
7
69
740
Personal history of diseases of the digestive system
Z87.1 [45542474]
Z87.1 [45542474]
—
-1.0e+50
—
—
—
—
4.7e-01
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
—
—
cases:10.14%
controls:6.56%
—
0
14
81
793
—
—
—
—
7
49
62
698
Examination for recruitment to armed forces
Z02.3 [45576125]
Z02.3 [45576125]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
69
742
Three-surface restoration
SFA30 [2001310360]
SFA30 [2001310360]
—
—
—
—
—
—
-1.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:8.03%
—
—
—
—
—
—
5
60
64
687
Uncompl labour/delivery livebirth
W90 [2002001277]
W90 [2002001277]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
6
78
773
—
—
—
—
—
0
6
69
741
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
F32.2 [45557202]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
78
772
—
—
—
—
—
—
Psychiatric treatment plan, standard
ICB01 [2001304098]
ICB01 [2001304098]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:0.94%
—
—
—
—
—
0
5
73
797
0
7
69
740
Body temperature
8310-5 [3020891]
8310-5 [3020891]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
6
69
741
alfacalcidol; oral, parenteral
A11CC03 [21600818]
A11CC03 [21600818]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:15.07%
controls:0.00%
—
—
—
—
—
—
—
11
0
62
802
—
epinephrine
S01EA01 [21603673]
S01EA01 [21603673]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.80%
cases:0.00%
controls:0.87%
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:1.47%
0
14
78
765
0
7
81
800
—
—
—
0
5
73
797
0
11
69
736
Periodontal treatment by dental hygienist
SDE02 [2001310350]
SDE02 [2001310350]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
0
9
81
798
—
—
—
—
—
clidinium and psycholeptics
A03CA02 [21600204]
A03CA02 [21600204]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
78
771
—
—
—
—
—
—
prazosin; oral
C02CA01 [21600411]
C02CA01 [21600411]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:6.49%
controls:0.00%
—
—
—
—
—
—
—
—
5
0
72
807
—
—
Postpartum check-up
SPAT1380 [2001700480]
SPAT1380 [2001700480]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.93%
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
0
15
78
764
0
9
81
798
—
—
—
—
0
12
69
735
hydroxyethylpromethazine, combinations
R06AD55 [21603490]
R06AD55 [21603490]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.44%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
78
760
—
—
—
—
—
—
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
2857-1 [3013603]
—
—
—
—
—
—
3.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.70%
controls:6.29%
—
—
—
—
—
—
6
47
63
700
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
22587-0 [3019832]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.18%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
0
17
78
762
—
—
—
—
0
7
73
795
—
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
14647-2 [3019900]
4.1e-01
3.9e-01
—
—
—
9.7e-01
4.4e-01
cases:16.67%
controls:11.68%
cases:11.11%
controls:7.81%
—
—
—
—
—
—
cases:21.92%
controls:9.60%
cases:34.78%
controls:25.57%
13
91
65
688
9
63
72
744
—
—
—
16
77
57
725
24
191
45
556
Melanocytic naevi
D22 [45595739]
D22 [45595739]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
0
8
69
739
glimepiride; oral
A10BB12 [21600761]
A10BB12 [21600761]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
0
5
81
802
—
—
—
—
other preparations, combinations; ointment
C05AX03 [21601631]
C05AX03 [21601631]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
0
6
73
796
—
Maternal and Fetal Medicine
OMOP4821963 [45756780]
OMOP4821963 [45756780]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.47%
0
14
78
765
—
—
—
—
—
0
11
69
736
dexchlorpheniramine, combinations
R06AB52 [21603467]
R06AB52 [21603467]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
6
78
773
—
—
—
—
—
0
6
69
741
Contraception intrauterine
W12 [2002001212]
W12 [2002001212]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.01%
—
0
9
81
798
—
—
—
—
0
15
69
732
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
—
—
—
—
—
—
8.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:3.35%
—
—
—
—
—
—
5
25
64
722
TREATMENT - Hemodialysis, center
TREATMENT-21 [2002330236]
TREATMENT-21 [2002330236]
1.0e+50
—
—
—
—
—
—
cases:8.97%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
—
7
0
71
779
—
—
—
—
—
—
Root filling of tooth with one root canal
SGB10 [2001310388]
SGB10 [2001310388]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.34%
—
—
—
—
—
—
0
10
69
737
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
78
773
—
—
—
—
—
—
Dysphagia
R13 [45573013]
R13 [45573013]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
69
742
Menopausal and female climacteric states
N95.1 [45548683]
N95.1 [45548683]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
7
69
740
Feeling anxious/nervous/tense
P01 [2002000798]
P01 [2002000798]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
78
774
—
—
—
—
—
—
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
MA2AE [2001306829]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.80%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
14
78
765
—
—
—
—
0
5
73
797
—
Cells panel - Urine sediment
58434-2 [40761535]
58434-2 [40761535]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
0
5
81
802
—
—
—
0
6
73
796
—
Trochanteric bursitis
M70.6 [45606304]
M70.6 [45606304]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
69
742
Child and Adolescent Psychiatry
OMOP4821986 [45756756]
OMOP4821986 [45756756]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.18%
cases:0.00%
controls:1.24%
—
—
—
—
—
—
cases:0.00%
controls:0.87%
cases:0.00%
controls:3.21%
0
17
78
762
0
10
81
797
—
—
—
0
7
73
795
0
24
69
723
ranitidine bismuth citrate; oral
A02BA07 [21600088]
A02BA07 [21600088]
1.3e+00
—
—
—
—
—
—
cases:7.69%
controls:2.18%
—
—
—
—
—
—
—
—
—
—
—
—
6
17
72
762
—
—
—
—
—
—
levonorgestrel
G03AC03 [21602499]
G03AC03 [21602499]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
78
767
—
—
—
—
—
—
General anaesthesia
WX402 [2001310806]
WX402 [2001310806]
—
—
—
—
—
—
9.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.70%
controls:3.48%
—
—
—
—
—
—
6
26
63
721
Internal derangement of knee, unspecified
M23.9 [45567507]
M23.9 [45567507]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
6
78
773
—
—
—
—
—
0
6
69
741
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
C03EA01 [21601543]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
0
5
81
802
—
—
—
—
Glaucoma suspect
H40.0 [45567051]
H40.0 [45567051]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
—
—
—
—
—
—
0
12
69
735
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
-4.8e-01
2.6e-01
-1.0e+50
—
—
-8.2e-01
-8.7e-01
cases:21.79%
controls:31.07%
cases:17.28%
controls:13.88%
cases:0.00%
controls:2.23%
—
—
—
—
cases:8.22%
controls:16.96%
cases:20.29%
controls:37.75%
17
242
61
537
14
112
67
695
0
18
81
789
—
—
6
136
67
666
14
282
55
465
Pulpit UNS
K04.09 [2000502704]
K04.09 [2000502704]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
7
69
740
calcium carbonate
A02AC01 [21600065]
A02AC01 [21600065]
1.0e+50
—
—
—
—
—
—
cases:10.26%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
—
8
0
70
779
—
—
—
—
—
—
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
14196-0 [3023520]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.70%
controls:1.74%
—
—
—
—
—
—
6
13
63
734
medroxyprogesterone; oral, parenteral
L02AB02 [21603821]
L02AB02 [21603821]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
69
742
Dental examination
Z01.2 [45581002]
Z01.2 [45581002]
1.6e-01
-1.0e+50
—
—
—
—
6.6e-01
cases:6.41%
controls:5.52%
cases:0.00%
controls:2.11%
—
—
—
—
—
—
—
—
cases:17.39%
controls:9.77%
5
43
73
736
0
17
81
790
—
—
—
—
12
73
57
674
diclofenac
D11AX18 [21602355]
D11AX18 [21602355]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
78
769
—
—
—
—
—
—
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
2.8e-01
8.0e-01
—
—
—
9.0e-01
5.7e-02
cases:10.26%
controls:7.96%
cases:7.41%
controls:3.47%
—
—
—
—
—
—
cases:10.96%
controls:4.74%
cases:10.14%
controls:9.64%
8
62
70
717
6
28
75
779
—
—
—
8
38
65
764
7
72
62
675
Lactate [Moles/volume] in Arterial blood
2518-9 [3018405]
2518-9 [3018405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
6
69
741
Feeling depressed
P03 [2002000800]
P03 [2002000800]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
78
774
—
—
—
—
—
—
Repair work or maintenance done on the aid
R5130 [2001310248]
R5130 [2001310248]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
69
742
Fall on same level involving ice and snow
W00 [45756242]
W00 [45756242]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.61%
0
8
78
771
—
—
—
—
—
0
12
69
735
Disease/condition unspecnature/site
A99 [2002000232]
A99 [2002000232]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
6
78
773
—
—
—
—
—
0
6
69
741
calcium carbonate; oral
A12AA04 [21600863]
A12AA04 [21600863]
1.0e+50
—
—
—
—
—
—
cases:10.26%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
—
8
0
70
779
—
—
—
—
—
—
General Practice Dentistry
1223G0001X [38003675]
1223G0001X [38003675]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.25%
controls:1.61%
—
—
—
—
—
—
5
12
64
735
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
1960-4 [3008152]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
0
8
69
739
hydrocortisone; local oral
A01AC03 [21600036]
A01AC03 [21600036]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.74%
0
11
78
768
—
—
—
—
—
0
13
69
734
Long-term monitoring of blood pressure
SPAT1100 [2001700201]
SPAT1100 [2001700201]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
7
78
772
—
—
—
—
0
5
73
797
—
Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma
93769-8 [1002102]
93769-8 [1002102]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.07%
—
—
—
—
—
—
0
8
69
739
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.70%
controls:1.87%
—
—
—
—
—
—
6
14
63
733
Respiratory infection other
R83 [2002000951]
R83 [2002000951]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.57%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
0
20
78
759
—
—
—
—
0
11
73
791
—
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
M01AC06 [21603965]
5.4e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:6.41%
controls:3.85%
cases:0.00%
controls:1.12%
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
5
30
73
749
0
9
81
798
—
—
—
0
9
73
793
—
ezetimibe; oral
C10AX09 [21601896]
C10AX09 [21601896]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
5
73
797
—
glycerol
A06AX01 [21600597]
A06AX01 [21600597]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.87%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
0
5
78
774
0
7
81
800
—
—
—
0
6
73
796
—
Other chest pain
R07.3 [45597166]
R07.3 [45597166]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.03%
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
8
78
771
0
6
81
801
—
—
—
—
0
6
69
741
Partial excision of meniscus of knee, arthroscopic
NGD05 [2001308109]
NGD05 [2001308109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
78
768
—
—
—
—
—
—
Functional dyspepsia
K30 [45591584]
K30 [45591584]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.34%
0
7
78
772
—
—
—
—
—
0
10
69
737
Clinic/Center
261Q00000X [38004207]
261Q00000X [38004207]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
78
773
—
—
—
—
—
—
tiotropium bromide; inhalant
R03BB04 [21603296]
R03BB04 [21603296]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.16%
cases:0.00%
controls:1.12%
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:1.12%
cases:0.00%
controls:2.01%
0
9
78
770
0
9
81
798
—
—
0
5
77
802
0
9
73
793
0
15
69
732
Psychiatric pharmacotherapy plan, not specified
IFA01 [2001304251]
IFA01 [2001304251]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
5
69
742
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
52
87
12.79
34.41
12.4
3.2
24.31
26.60
%
0.44
52
80
54
108
11.00
30.32
12.0
2.9
12.40
15.96
umol/l
2.15
54
97
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
29
12
34.84
22.66
5.1
8.1
0.28
0.33
iu/ml
—
15
6
26
33
10.67
20.28
4.0
3.3
198.46
177.27
%
0.70
26
33
38
78
7.70
19.71
21.2
4.7
23.29
23.46
mmol/l
0.15
38
78
44
113
6.66
18.04
8.9
3.1
2.81
1.87
e6/l
0.24
27
59
16
0
+∞
17.22
11.4
0.0
6.01
—
mmol/l
—
16
0
44
125
5.93
15.86
8.7
3.0
0.54
0.74
e6/l
0.39
28
70
25
41
8.06
15.62
10.3
2.2
28.67
77.13
ml/min/173m2
—
9
16
57
211
5.64
14.89
13.2
3.0
0.22
0.31
e6/l
0.29
46
157
23
41
7.19
13.19
1.9
1.6
—
—
—
0
0
21
34
7.75
13.13
2.4
1.6
—
—
—
0
0
19
12
19.66
12.83
1.9
1.8
—
—
—
0
0
23
24
12.46
12.69
2.4
1.6
183.61
163.17
u/ml
0.14
18
12
23
26
11.48
12.20
2.3
1.5
—
—
—
0
0
11
0
+∞
11.71
1.4
0.0
—
—
—
0
0
11
0
+∞
11.71
1.4
0.0
—
—
—
0
0
31
82
5.24
11.69
21.7
9.7
23.89
24.40
mmol/l
0.38
31
82
22
25
11.26
11.62
3.0
1.7
121.83
179.88
au/ml
—
6
8
25
58
5.58
10.87
6.4
3.2
—
—
—
0
0
49
195
4.32
10.83
14.2
4.0
34.62
14.76
mg/mmol
1.18
43
128
45
173
4.20
10.34
3.4
2.0
—
—
—
0
0
17
16
12.79
9.79
13.9
5.4
80.24
64.80
%
2.09
17
16
13
6
24.94
9.66
1.2
1.0
—
—
—
0
0
29
90
4.28
8.73
22.3
8.0
103.34
104.90
mmol/l
0.71
29
90
20
32
7.72
8.64
2.8
1.5
—
—
—
0
0
15
15
11.74
8.41
2.5
1.2
3.13
1.50
u/ml
—
8
6
13
11
13.56
7.87
1.2
1.1
—
—
—
0
0
22
63
4.30
7.26
3.0
2.8
66.94
28.00
u/l
0.81
17
50
14
17
9.52
7.14
2.6
1.2
5.56
3.40
u/ml
—
9
10
40
174
3.34
7.14
4.5
2.1
5.79
0.88
mg/l
1.09
35
139
27
92
3.76
7.01
3.5
1.8
—
—
—
0
0
32
123
3.49
6.93
4.3
3.1
352.08
771.73
ng/l
0.50
26
83
22
66
4.09
6.80
30.8
10.9
0.53
0.78
mmol/l
0.10
22
56
27
95
3.63
6.66
3.4
1.7
—
—
—
0
0
24
79
3.78
6.51
23.9
6.5
1.24
1.28
mmol/l
0.02
18
59
30
123
3.16
5.73
4.0
1.9
—
—
—
0
0
70
458
3.38
5.72
20.9
9.3
4.41
3.81
e9/l
1.04
64
408
15
30
5.78
5.56
24.4
18.2
24.00
24.02
mmol/l
0.01
15
30
12
18
7.51
5.46
1.6
1.1
—
—
—
0
0
12
21
6.42
4.95
4.3
2.5
10.57
2.50
index
—
7
12
59
369
2.74
4.91
13.5
6.2
16.22
17.04
umol/l
0.06
59
353
13
26
5.66
4.85
2.5
1.3
—
—
—
0
0
12
23
5.85
4.65
1.4
1.3
—
—
—
0
0
63
417
2.70
4.52
11.4
3.6
0.00
0.00
estimate
-0.00
12
79
55
344
2.54
4.40
4.9
2.7
—
—
estimate
—
0
0
8
9
9.61
4.37
3.7
1.1
0.00
0.00
g/l
—
8
9
63
421
2.65
4.37
11.4
3.6
0.00
0.00
estimate
-0.00
12
82
14
42
3.76
4.24
26.2
14.7
92.06
95.09
%
0.87
14
42
8
10
8.64
4.15
1.1
1.5
—
—
—
0
0
63
427
2.58
4.14
11.5
3.7
0.00
0.00
estimate
-0.00
12
77
8
11
7.85
3.95
2.8
1.4
—
—
—
0
0
8
11
7.85
3.95
2.5
1.3
—
—
—
0
0
10
20
5.48
3.81
1.5
1.2
—
—
—
0
0
9
18
5.43
3.47
13.0
3.5
14.37
11.83
pmol/l
—
9
18
7
10
7.48
3.43
1.3
1.5
—
—
—
0
0
7
10
7.48
3.43
1.3
1.4
—
—
—
0
0
7
10
7.48
3.43
1.3
1.5
—
—
—
0
0
7
10
7.48
3.43
1.3
1.5
—
—
—
0
0
9
19
5.14
3.33
2.1
2.2
—
—
—
0
0
6
7
9.07
3.31
5.2
3.0
19.50
17.86
index
—
6
7
6
7
9.07
3.31
4.5
6.9
104.83
103.14
%
—
6
7
10
25
4.36
3.19
2.8
1.5
—
—
—
0
0
45
285
2.16
3.17
2.4
2.0
102.89
94.74
pmol/l
0.63
26
155
8
16
5.37
3.13
7.5
2.5
117.62
132.50
g/l
—
8
10
10
26
4.19
3.09
1.4
1.4
—
15.25
—
0
6
10
26
4.19
3.09
2.8
1.6
—
—
—
0
0
5
5
10.48
3.01
3.0
1.4
—
—
—
0
0
5
5
10.48
3.01
1.6
1.4
—
—
—
0
0
7
13
5.73
2.93
1.3
1.4
—
—
—
0
0
7
13
5.73
2.93
1.3
1.4
—
—
—
0
0
7
14
5.32
2.78
2.7
1.6
—
—
—
0
0
6
10
6.33
2.74
1.0
1.2
99.67
91.70
%
—
6
10
7
15
4.96
2.65
1.3
1.5
—
—
—
0
0
5
9
5.81
2.24
1.8
1.9
—
—
—
0
0
7
19
3.90
2.20
1.1
1.1
—
—
—
0
0
6
14
4.51
2.19
1.7
1.2
—
—
—
0
0
7
20
3.70
2.10
1.1
1.1
—
—
—
0
0
6
15
4.20
2.07
2.7
1.9
—
—
—
0
0
75
645
1.98
1.61
53.5
11.7
56.44
89.40
ml/min/173m2
8.94
65
581
5
15
3.46
1.54
1.4
1.1
—
—
—
0
0
5
15
3.46
1.54
1.4
1.1
—
—
—
0
0
5
15
3.46
1.54
1.0
1.1
—
—
—
0
0
14
235
0.52
1.42
1.7
1.9
—
—
—
0
0
6
23
2.72
1.39
1.8
1.5
—
—
—
0
0
5
19
2.72
1.23
1.8
1.5
—
—
—
0
0
8
39
2.15
1.18
1.9
1.5
—
—
—
0
0
82
756
1.95
1.04
56.4
12.7
17.89
21.62
mg/l
1.03
74
608
0
28
0.00
0.99
0.0
1.3
—
—
—
0
0
83
770
2.00
0.97
31.6
10.3
22.19
25.88
u/l
2.05
83
756
60
517
1.48
0.94
6.6
3.5
51.15
35.18
u/l
0.41
60
498
6
28
2.22
0.93
1.7
1.1
0.91
0.83
g/l
—
6
28
8
48
1.73
0.81
1.3
1.2
—
—
—
0
0
5
26
1.98
0.72
1.0
1.1
1.46
1.62
g/l
—
5
26
7
42
1.72
0.70
1.1
1.5
—
—
—
0
0
21
160
1.41
0.61
1.7
1.6
—
—
—
0
0
0
21
0.00
0.61
0.0
1.0
—
—
—
0
0
0
22
0.00
0.60
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
27
230
1.25
0.37
11.5
2.9
0.00
0.00
estimate
—
9
67
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
10
119
0.82
0.16
2.0
2.1
—
—
—
0
0
25
228
1.13
0.15
6.1
3.7
91.42
30.09
ng/l
0.51
19
140
8
98
0.80
0.14
2.0
1.9
—
—
—
0
0
24
220
1.12
0.13
12.7
3.5
0.00
0.01
estimate
—
10
73
62
599
1.11
0.13
4.4
4.0
—
—
—
0
0
16
175
0.90
0.09
1.7
2.6
—
—
—
0
0
6
55
1.10
0.09
1.3
1.3
—
—
—
0
0
84
829
1.20
0.08
85.3
20.4
118.24
135.50
g/l
11.85
84
822
84
829
1.20
0.08
90.1
20.8
35.77
40.49
%
10.48
84
822
84
829
1.20
0.08
84.7
20.0
90.92
89.70
fl
1.35
84
822
15
162
0.91
0.06
1.6
2.4
—
—
—
0
0
19
180
1.07
0.04
3.4
5.1
1.76
2.07
ug/l
0.26
19
164
32
312
1.04
0.02
11.8
3.4
0.00
0.01
estimate
0.49
11
67
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
13.50
—
0
8
0
5
0.00
-0.00
0.0
1.4
—
0.03
—
0
5
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
5
49
1.02
-0.00
1.6
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
4.70
—
0
5
0
5
0.00
-0.00
0.0
2.2
—
10.44
—
0
5
0
6
0.00
-0.00
0.0
3.3
—
166.28
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint D3_NONAIHA_OTHER and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have D3_NONAIHA_OTHER.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: D3_NONAIHA_OTHER – Haemolytic-uraemic syndrome
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data